Dermata reports positive Phase 3 STAR-1 data, Q2 2025 cash $6.5M

Dermata Therapeutics, Inc.

2025-Q2 EPS reported -$5.18

XYNGARI™ Phase 3 STAR-1 met all three co-primary endpoints with statistical significance at weeks 4 and 12.
Raised $8.8M gross proceeds in H1 2025; cash $6.5M at June 30, expected to fund operations into Q2 2026.
R&D expenses $0.6M in Q2 2025 vs $2.0M in Q2 2024, decrease due to STAR-1 completion.
G&A expenses $1.2M in Q2 2025 vs $0.9M in Q2 2024; increase from compliance and personnel costs.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.